Integrative molecular concept modeling of prostate cancer progression (original) (raw)

• Jemal, A. et al. Cancer statistics, 2005. CA Cancer J. Clin. 55, 10–30 (2005).
  Article PubMed Google Scholar
• Nelson, P.S. Predicting prostate cancer behavior using transcript profiles. J. Urol. 172, S28–S32 (2004).
  CAS PubMed Google Scholar
• Ashida, S. et al. Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene-expression profiles of prostate cancers and PINs. Cancer Res. 64, 5963–5972 (2004).
  Article CAS PubMed Google Scholar
• Bostwick, D.G. & Qian, J. High-grade prostatic intraepithelial neoplasia. Mod. Pathol. 17, 360–379 (2004).
  Article PubMed Google Scholar
• De Marzo, A.M., Marchi, V.L., Epstein, J.I. & Nelson, W.G. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am. J. Pathol. 155, 1985–1992 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• DeMarzo, A.M., Nelson, W.G., Isaacs, W.B. & Epstein, J.I. Pathological and molecular aspects of prostate cancer. Lancet 361, 955–964 (2003).
  Article CAS PubMed Google Scholar
• Gleason, D.F. & Mellinger, G.T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J. Urol. 111, 58–64 (1974).
  Article CAS PubMed Google Scholar
• Humphrey, P.A. Gleason grading and prognostic factors in carcinoma of the prostate. Mod. Pathol. 17, 292–306 (2004).
  Article PubMed Google Scholar
• True, L. et al. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc. Natl. Acad. Sci. USA 103, 10991–10996 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Best, C.J. et al. Molecular differentiation of high- and moderate-grade human prostate cancer by cDNA microarray analysis. Diagn. Mol. Pathol. 12, 63–70 (2003).
  Article CAS PubMed Google Scholar
• Lapointe, J. et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc. Natl. Acad. Sci. USA 101, 811–816 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Singh, D. et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1, 203–209 (2002).
  Article CAS PubMed Google Scholar
• Welsh, J.B. et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res. 61, 5974–5978 (2001).
  CAS PubMed Google Scholar
• Vanaja, D.K., Cheville, J.C., Iturria, S.J. & Young, C.Y. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res. 63, 3877–3882 (2003).
  CAS PubMed Google Scholar
• Mootha, V.K. et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267–273 (2003).
  Article CAS PubMed Google Scholar
• Segal, E., Friedman, N., Koller, D. & Regev, A. A module map showing conditional activity of expression modules in cancer. Nat. Genet. 36, 1090–1098 (2004).
  Article CAS PubMed Google Scholar
• Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545–15550 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Rhodes, D.R. & Chinnaiyan, A.M. Integrative analysis of the cancer transcriptome. Nat. Genet. 37 (Suppl.), S31–S37 (2005).
  Article CAS PubMed Google Scholar
• Rhodes, D.R. et al. Mining for regulatory programs in the cancer transcriptome. Nat. Genet. 37, 579–583 (2005).
  Article CAS PubMed Google Scholar
• Tomlins, S.A. et al. Whole transcriptome amplification for gene expression profiling and development of molecular archives. Neoplasia 8, 153–162 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Rhodes, D.R. et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6, 1–6 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Varambally, S. et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8, 393–406 (2005).
  Article CAS PubMed Google Scholar
• Quinn, D.I., Henshall, S.M. & Sutherland, R.L. Molecular markers of prostate cancer outcome. Eur. J. Cancer 41, 858–887 (2005).
  Article CAS PubMed Google Scholar
• Sato, K. et al. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J. Natl. Cancer Inst. 91, 1574–1580 (1999).
  Article CAS PubMed Google Scholar
• Kristiansen, G. et al. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J. Pathol. 205, 359–376 (2005).
  Article CAS PubMed Google Scholar
• Moore, S. et al. Loss of stearoyl-CoA desaturase expression is a frequent event in prostate carcinoma. Int. J. Cancer 114, 563–571 (2005).
  Article CAS PubMed Google Scholar
• Stuart, R.O. et al. In silico dissection of cell-type-associated patterns of gene expression in prostate cancer. Proc. Natl. Acad. Sci. USA 101, 615–620 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Sumitomo, M. et al. Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN. Cancer Cell 5, 67–78 (2004).
  Article CAS PubMed Google Scholar
• Dhanasekaran, S.M. et al. Delineation of prognostic biomarkers in prostate cancer. Nature 412, 822–826 (2001).
  Article CAS PubMed Google Scholar
• Koyabu, Y., Nakata, K., Mizugishi, K., Aruga, J. & Mikoshiba, K. Physical and functional interactions between Zic and Gli proteins. J. Biol. Chem. 276, 6889–6892 (2001).
  Article CAS PubMed Google Scholar
• Paris, P.L. et al. Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum. Mol. Genet. 13, 1303–1313 (2004).
  Article CAS PubMed Google Scholar
• Nupponen, N.N., Kakkola, L., Koivisto, P. & Visakorpi, T. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am. J. Pathol. 153, 141–148 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Tomlins, S.A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644–648 (2005).
  Article CAS PubMed Google Scholar
• Tomlins, S.A. et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 66, 3396–3400 (2006).
  Article CAS PubMed Google Scholar
• Glinsky, G.V., Glinskii, A.B., Stephenson, A.J., Hoffman, R.M. & Gerald, W.L. Gene expression profiling predicts clinical outcome of prostate cancer. J. Clin. Invest. 113, 913–923 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Konishi, N., Shimada, K., Ishida, E. & Nakamura, M. Molecular pathology of prostate cancer. Pathol. Int. 55, 531–539 (2005).
  Article CAS PubMed Google Scholar
• Trotman, L.C. et al. Identification of a tumour suppressor network opposing nuclear Akt function. Nature 441, 523–527 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Tran, H., Brunet, A., Griffith, E.C. & Greenberg, M.E. The many forks in FOXO's road. Sci. STKE 2003, RE5 (2003).
  Article PubMed Google Scholar
• Vailancourt, L. et al. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. Am. J. Surg. Pathol. 20, 86–93 (1996).
  Article CAS PubMed Google Scholar
• Tomlins, S.A., Rubin, M.A. & Chinnaiyan, A.M. Integrative biology of prostate cancer progression. Ann. Rev. Pathol. Mech. Dis. 1, 243–271 (2006).
  Article CAS Google Scholar
• De Marzo, A.M. et al. Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. J. Cell. Biochem. 91, 459–477 (2004).
  Article CAS PubMed Google Scholar
• Fischer, A.H., Bardarov, S., Jr. & Jiang, Z. Molecular aspects of diagnostic nucleolar and nuclear envelope changes in prostate cancer. J. Cell. Biochem. 91, 170–184 (2004).
  Article CAS PubMed Google Scholar
• Ruggero, D. & Pandolfi, P.P. Does the ribosome translate cancer? Nat. Rev. Cancer 3, 179–192 (2003).
  Article CAS PubMed Google Scholar
• Hendriksen, P.J. et al. Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res. 66, 5012–5020 (2006).
  Article CAS PubMed Google Scholar
• Stanbrough, M. et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 66, 2815–2825 (2006).
  Article CAS PubMed Google Scholar
• Chen, C.D. et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10, 33–39 (2004).
  Article PubMed CAS Google Scholar
• Feldman, B.J. & Feldman, D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 1, 34–45 (2001).
  Article CAS PubMed Google Scholar
• Lin, B. et al. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res. 59, 4180–4184 (1999).
  CAS PubMed Google Scholar
• Rhodes, D.R. et al. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc. Natl. Acad. Sci. USA 101, 9309–9314 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Storey, J.D. & Tibshirani, R. Statistical significance for genomewide studies. Proc. Natl. Acad. Sci. USA 100, 9440–9445 (2003).
  Article CAS PubMed PubMed Central Google Scholar